BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Regen BioPharma Announces HemaXellerate I™ Efficacy Data In Animal Model Of Aplastic Anemia


12/11/2013 10:29:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - December 11, 2013) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today results of ongoing experiments in collaboration with Dr. Wei-Ping Min of the University of Western Ontario using HemaXellerate I to treat an immune competent animal model of aplastic anemia.

The HemaXellerate I study utilized mice that were bone marrow compromised, in a similar manner to bone marrow damage in patients with aplastic anemia. Subsequently animals were treated with increasing doses of HemaXellerate I. A dose-dependent increase in bone marrow repair was noted, as observed by acceleration of blood cell production after treatment with the chemotherapeutic agent. In contrast to previous experiments reported by the company, in this set of experiments, recipient animals possessed an intact immune system, implying that the HemaXellerate I product does not trigger adverse immune reactions.

"These data are part of the FDA requested experiments, which we are compiling to address the second series of questions that the FDA has asked us subsequent to our filing of IND #15376 for use of HemaXellerate I in the treatment of drug refractory aplastic anemia." Said David Koos, CEO of Regen. "By leveraging our SAB members, collaborators such as Dr. Wei-Ping Min, and contractors such as Cook General Biotechnology, who manufactures GMP-grade HemaXellerate I, the Company believes it is well positioned to develop the product as the first regenerative medicine solution for drug resistant aplastic anemia, an indication which qualifies for Orphan Drug Status."

Regen's focus on aplastic anemia is based on the ability of specific cells from the lining of blood vessels to stimulate repair of injured bone marrow stem cells, which are responsible for production of blood cells. The rationale for this product was published in a peer-reviewed publication by Regen last year, which is available freely at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf.

"Our group is optimistic about the results announced today, and we are in the process of conducting additional safety studies requested by the FDA before initiation of clinical trials," stated Dr. Wei-Ping Min, Professor at the University of Western Ontario, Canada. "The finding of efficacy of HemaXellerate in an immune competent recipient is intriguing and suggests this cellular product is relatively innocuous from an immunological perspective."

About Regen BioPharma: Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website http://www.regenbiopharma.com/

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


Contact:

Bio-Matrix Scientific Group, Inc. and
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
www.regenbiopharma.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES